Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - AccuredRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Fate Therapeutics (FATE) Non-Current Deffered Revenue (2016 - 2022)

Fate Therapeutics (FATE) has disclosed Non-Current Deffered Revenue for 11 consecutive years, with $12.4 million as the latest value for Q3 2022.

  • For the quarter ending Q3 2022, Non-Current Deffered Revenue fell 61.9% year-over-year to $12.4 million, compared with a TTM value of $12.4 million through Sep 2022, down 61.9%, and an annual FY2021 reading of $27.1 million, down 41.06% over the prior year.
  • Non-Current Deffered Revenue was $12.4 million for Q3 2022 at Fate Therapeutics, down from $17.7 million in the prior quarter.
  • Across five years, Non-Current Deffered Revenue topped out at $54.7 million in Q2 2020 and bottomed at $198000.0 in Q1 2018.
  • Average Non-Current Deffered Revenue over 5 years is $19.9 million, with a median of $12.4 million recorded in 2022.
  • The sharpest move saw Non-Current Deffered Revenue tumbled 91.4% in 2018, then surged 3122.22% in 2019.
  • Year by year, Non-Current Deffered Revenue stood at $7.5 million in 2018, then tumbled by 49.67% to $3.8 million in 2019, then soared by 1119.1% to $46.0 million in 2020, then tumbled by 41.06% to $27.1 million in 2021, then plummeted by 54.26% to $12.4 million in 2022.
  • Business Quant data shows Non-Current Deffered Revenue for FATE at $12.4 million in Q3 2022, $17.7 million in Q2 2022, and $22.5 million in Q1 2022.